Retatrutida is a new-generation investigational peptide that acts as a triple agonist for GLP-1, GIP and glucagon receptors
Diabetes guidelines recommend these GLP-1 RAs as pharmacologic agents in patients with ASCVD or with high-risk indicators for cardiovascular disease
Compared with the 1.5 mg dulaglutide group, body weight was significantly decreased in the 3.0 mg (ETD 0.9, 95% CI 1.4 to 0.4 kg
It is especially this kind of adipose tissue that is believed to drive a large part of the pathological effects of excess body weight ( The reductions in ROS and systemic inflammation, in combination with improvements in the other cardiometabolic parameters, are also thought to mediate the substantiated but so far formally unconfirmed kidney-protective effects of GLP-1 RAs, which may also directly or indirectly carry a HF-related benefit, considering that CKD is a prominent risk factor for HF (von Scholten et al., 2022)
The enzyme dipeptidyl peptidase-4 (DPP-4) rapidly degrades circulating GLP-1, which is why pharmaceutical versions are chemically modified to resist this breakdown and maintain therapeutic levels for extended periods
When muscle mass drops too much: Your metabolism slows down , so you burn fewer calories You lose strength, stability, and energy You may regain fat more easily after stopping the medication You increase your risk of long-term frailty and poor body composition The goal isnt just to lose weight its to lose fat while keeping (or gaining) strength
